• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FCRI Index

FCRI Index

January 11, 2021

CWW Unveils FCRI, a Stock Index of 10 Publicly Traded Clinical Trials Companies

This week, CenterWatch Weekly (CWW) is unveiling the First Clinical Research Index (FCRI), a stock index of 10 publicly traded clinical trials companies. Once a month, CWW will publish the prior month’s calculation of the FCRI to show how the industry’s top stocks are faring compared to three other widely followed indices: the Standard & Poor’s (S&P) 500 index, the S&P Pharmaceutical Index and the S&P Biopharmaceutical Index. For more information about the index, read on.

Notes on Indices

First Clinical Research Index (FCRI). Calculated as the mean average percentage change from baseline, dividends excluded, adjusted for stock splits. In other words, the indices are not weighted for stock price or market capitalization. Prices are in local currencies. Index components may change from time to time based on new listings, mergers and other factors. Components include 10 publicly traded clinical research stocks: CMIC (2309:JP), EPS (4282:JP), Hangzhou Tigermed Consulting (300347:CH), ICON (ICLR:US), IQVIA Holdings (IQV:US), Medpace Holdings (MEDP:US), PRA Health Sciences (PRAH:US) and Syneos Health (SYNH:US).

S&P 500 Index (SPX). Capitalization-weighted representative sample of 500 mostly large-capitalization companies in leading industries of the U.S. economy.

S&P 500 Pharmaceutical Index (S5PHARX). Capitalization-weighted S&P 500 companies engaged in research, development or production of pharmaceuticals.

S&P 500 Biotechnology Index (S5BIOTX). Capitalization-weighted S&P 500 companies primarily involved in development, manufacturing or marketing of products based on advanced biotechnology research.

Stock and index prices are available at http://www.bloomberg.com/ and http://bigcharts.marketwatch.com/industry/bigcharts-com/industrychart.asp.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing